Baolan Li

机构：Beijing Chest Hospital, Shaanxi University of Chinese Medicine · ORCID：0000-0003-2621-6267

发表论文 59 篇 · 总被引 2387 次 · h-index 20

代表论文

• Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study (2021 · Journal of Thoracic Oncology · 被引 154)
• Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 133)
• Role of aneuploid circulating tumor cells and CD31 + circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC (2021 · Molecular Oncology · 被引 34)
• Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients (2020 · Journal of Immunotherapy · 被引 32)
• Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS) (2024 · 癌症：英文版 · 被引 30)
• Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer (2024 · Cancer Cell · 被引 24)